Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: A meta-analysis
Article first published online: 28 SEP 2010
© 2010 The Japan Society of Hepatology
Volume 40, Issue 10, pages 943–953, October 2010
How to Cite
Zhong, J.-H. and Li, L.-Q. (2010), Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: A meta-analysis. Hepatology Research, 40: 943–953. doi: 10.1111/j.1872-034X.2010.00710.x
- Issue published online: 28 SEP 2010
- Article first published online: 28 SEP 2010
- Received 1 March 2010; revision 9 May 2010; accepted 14 June 2010.
- hepatocellular carcinoma;
- transarterial chemoembolization
Aim: The efficacy of transarterial chemoembolization (TACE) for inoperable hepatocellular carcinoma (HCC) is positive, but for postoperative HCC, many studies have reported controversial results. The present study aimed to evaluate the efficacy of postoperative adjuvant TACE for participants with HCC.
Methods: Electronic and manual searches were conducted to identify randomized controlled trials (RCT) evaluating postoperative adjuvant TACE for participants with HCC.
Results: Six RCT totaling 659 participants, of whom almost all were of stage IIIA HCC, were included. For the 1-year tumor recurrence rate, hepatectomy plus TACE showed statistically significant less incidence of recurrence, with a pooled risk ratio (RR) of 0.68 (95% confidence interval [CI] = 0.55–0.84, P = 0.0003). For 1-year mortality, the trials were favorable for TACE with a pooled risk ratio of 0.48 (95% CI = 0.35–0.65, P < 0.00001). For 3-year mortality, the trials also revealed statistically significant less incidence, with a pooled risk ratio of 0.76 (95% CI = 0.64–0.90, P = 0.002). However, for 5-year mortality, TACE did not demonstrate statistically significant less incidence (RR = 0.94, 95% CI = 0.81–1.08, P = 0.36). Transient fever and nausea/vomiting were reported as side-effects of TACE but were well tolerated by most participants.
Conclusion: Postoperative adjuvant TACE seems promising for participants with HCC with risk factors (multiple nodules of >5 cm or vascular invasion) but requires further trial.